Condition

Tyrosine Kinase Inhibitor

ClinicalTrials.gov condition label

Clinical trials3

Recruiting2

Common interventions4

Lead sponsors shown3

Clinical trials

3 shown

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung CancerNCT06755684 · 2024-11-07

ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)NCT05221372 · 2017-02-02

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R MutationNCT05263947 · 2022-01-30

Common interventions

Befotertinib combined BevacizumabDRUG1 Befotertinib combined platinum-based double chemotherapyDRUG1 BevacizumabDRUG1 IcotinibDRUG1

Leading sponsors

Erasmus Medical Center1 Peng Zhang1 Tianjin Medical University Cancer Institute and Hospital1

Trial status mix

RECRUITING2

COMPLETED1

Phase mix

PHASE22

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.